2015 top banner
Primary Antibodies  >  Transcription Factor Antibodies

NFkB p65 phospho S276 Antibody

Rabbit Polyclonal
NCI Collaboration
Order Offline
Rockland Affinity purified Anti-NFKB p65 (Rel A) pS276 600-401-264 lot 24040 was probed against Normal (Lane 1) and TNFalpha (Lane 2) Stimulated HeLa whole cell lysates.  A band was observed between 55 and 72 kD corresponding to the expected MW of NFkB p65.  The observed higher MW bands have not been characterized.
View All Images
100 µg
Ships next business day.

NFkB p65 phospho S276 Antibody Properties

Anti-NFKB p65 (Rel A) pS276 (RABBIT) Antibody - 600-401-264
Target Species
Known Cross Reactivity
ELISA : 1:5,000 - 1:25,000
Western Blot : 1:1,000
Other Dilution: User Optimized
Physical State
Liquid (sterile filtered)
Shipping Condition
Dry Ice
1.0 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
Download CofA:

NFkB p65 phospho S276 Antibody Description

NF?B was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NF?B bound to I?B. NF?B was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), cRel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NF?B subunit p65, similar to p50/p65 heterodimers. Low levels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by I?B-a. I?B-a ?binds to the p65 subunit preventing nuclear localization and DNA binding. Activators mediate a rapid phosphorylation of I?B by I?B kinase (IKK) which results in subsequent ubiquitination and proteolytic degradation. NF?B is then transported to the nucleus, where it activates transcription of target genes through binding to NF?B target sequences within the promoter. The HTLV-I protein Tax can induce constitutive NF?B activation through phosphorylation of both I?B-a and I?B-ß. The transforming protein Tax inhibits p53 transcriptional activity through the NF?B signaling pathway, specifically via the p65 (RelA) subunit. The inhibition of p53 activity is dependent upon phosphorylation of p65 (RelA) at S536 by the upstream kinase IKKß.
NFKB, nfkb, NF-kB, NF-kappaB, NFkappaB
NFkB p65 (Rel A) peptide corresponding to a region near phospho Serine 276 of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH). 
Immunogen Type
Post Translational Modification
Storage Condition
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Application Note
This phospho specific polyclonal antibody reacts human pS276 p65 and shows minimal reactivity by western blot with non-phosphorylated p65 and minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide.  Although not tested, this antibody is likely functional in immunohistochemistry and immunoprecipitation. For immunoblotting a 1:1,000 dilution is recommended.  A 65 kDa band corresponding to human p65 is detected.  HeLa cells or TNF inducible KBM-5 cells can be used as a positive control.
This product was prepared from monospecific antiserum by delipidation and defibrination. This phospho specific polyclonal antibody is specific for phosphorylated pS276 human p65.  Reactivity with non-phosphorylated p65 is minimal. Cross reactivity with pS276 phosphorylated p65 from mouse, rat or other species has not been determined.
Disclaimer Note-General
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
General Reference
Jeong S.J., Pise-Masison C.A., Radonovich M.F., Park H.U., and Brady J.N. (2005) A Novel NF-?B Pathway Involving IKKß?and p65/RelA Ser-536 Phosphorylation Results in p53 Inhibition in the Absence of NF?B Transcriptional Activity. J. Biol. Chem. 280 (11): 10326-10332. Baldwin, A.S. (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF?B. J. Clinical Investigation 107: 241-246. Baldwin, A.S. (2001) Series introduction: the transcription factor NF?B and human disease. J. Clinical Investigation 107: 3-6.
Specific Reference
Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, and Aggarwal BB (2002) Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 169-11: 6490-7. Kawakami A, Osaka M, Aikawa M, et al. (2008) Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ. Res. Dec 5;103(12):1402-1409.
Log in to submit your product review.

Product Type
Proteins and Peptides;
Catalog Number

Product Type
Proteins and Peptides;
Catalog Number

Product Type
Primary Antibodies;
Reacts With
human, mouse, rat, chicken
Catalog Number

Product Type
Primary Antibodies;
Reacts With
Catalog Number

Product Label


Conjugation Reference
Molecular Weight
Excitation Wavelength
Conjugation Chemistry